AKT1 and Timothy syndrome: Another modality is topical mTOR inhibitors, which serve as targeted treatment agents for TS regarding the role of the Pi3K–AKT–mTOR (phosphoinositide 3-kinase- protein kinase B-mammalian target rapamycin) pathway in etiopathogenesis.